Table 2.
Results of the PTT as a concomitant treatment
| Author/year | n | Type of therapy | PTD average daily use (hours) | PTD average duration (months) | Gain in SPL (cm, p) | Mean curvature ° (SD) | Change in curvature (°, %) |
|---|---|---|---|---|---|---|---|
| Gallo/201923 | 1. 76 2. 45 3. 56 |
1. L-arginine and pentoxifylline 2. L-arginine, pentoxifylline and verapamil 3. L-arginine, pentoxifylline, verapamil and PTD |
1. 0 2. 0 3. 2-8 |
6 | 1. -0.1 p=0.33 2. 0.1 p=0.37 3. 0.7 p=0.1 |
1. 24.2 (9) 2. 25.4 (16.8) 3. 34.3 (17.9) |
1. 0.5 (2.1) p=0.36 2. 1.3 (5.1) p=0.34 3. 8.2 (23.9) p=0.006 |
| Fernández-Pascual/201927 | 1. 50 2. 94 |
1. CCH + PNT +PTD modelling, tadalafil, pentoxifylline 2. CCH +PTD modelling, tadalafil, pentoxifylline |
1. 6-8 2. 6-8 |
2 | 1. +0.3 (0.5); p<0.001 2. +0.1 (0.3); p<0.01 |
1. 55.3 (14.5) 2. 50.6 (15.7) |
1. 19.2 (6.1)°, 36.2 (12.5)% 2. 12.7 (5.0)°, 28.1(14.5)% |
| Alom/201926 | 1. 52 2. 45 3. 16 |
1. CCH+ modelling 2. CCH modelling + PTD 3. CCH + modelling + RestoreX |
1. 0 2. 1,9 3. 0,9 |
6 | 1. -0.7 2. -0.4 3. +1.9 p=0.56 (group 2 vs group 1) p <0.0001 (group 3 vs group 1) p <0.001 (group 3 vs group 2) |
median (IQR): 1. 60 (45-75) 2. 61.5 (45-75) 3. 65 (50-85) |
1. 20,3 °, 31.2% 2. 19,2 °, 30.2% 3. 33,8 ° 49.4% |
| Ziegelmann/201712 | 1. 35 2. 16 |
1. CCH + modelling +PTD 2. CCH +modelling |
1. 1.7 2. 0 |
6 | 1. +0.4; p=0.25 2. -0.35; p=0.48 |
1. 67.4 (25.1) 2. 62.1 (24.9) |
1. 19.6 (16.1)°, 32.6 (26.8) % 2. 23.6 (19.9)°, 27.5 (30.1) % |
| Yafi/201525 | 1. 78 2. 34 |
1. IFN a-2b 2. IFN a-2b + PTD |
1. N/A 2. N/A |
N/A | 1. +1.3 (0.8) 2. +2.4 (0.9) p=0.5567 (group 1 vs group 2) |
1. 42.3 (20.8) 2. 42.2 (14.6) |
1. 9.9 (11.8) 2. 8.1 (16.0) p= 0.4894 (group 1 vs group 2) |
| Abern/201224 | 1. 39 2. 35 |
1. verapamil, PTD, oral pentoxifylline and L-arginine 2. verapamil, oral pentoxifylline and L-arginine |
1. 3.3 2. 0 |
6 | 1. +0,3; p = 0.06 2. -0,7; p = 0.46 |
1. 44.4 (40.0–48.7) 2. 36.6 (33.5–39.7) (95% CI) |
1. 11 ° 2. 15.1 |
SD = standard deviation; PTT = penile traction therapy; PTD = penile traction device; SPL = stretched penile length; CCH = collagenase clostridium histolyticum; PNT = percutaneous needle tunneling; IQR = interquartile range; IFN = interferon.